Adverum Biotechnologies (ADVM) News Today $0.90 -0.11 (-10.89%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$0.88▼$1.0450-Day Range$0.81▼$1.2652-Week Range$0.53▼$2.34Volume408,462 shsAverage Volume382,507 shsMarket Capitalization$90.93 millionP/E RatioN/ADividend YieldN/APrice Target$3.50 HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAdverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Societyfinance.yahoo.com - December 7 at 7:57 PMAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Short Interest Updateamericanbankingnews.com - December 2 at 1:26 AMPromising Developments in Adverum Biotechnologies’ Gene Therapy Candidate, Ixo-Vec, Drive Graig Suvannavejh’s Bullish Ratingmarkets.businessinsider.com - November 21 at 8:15 AMRBC Capital Reaffirms Their Hold Rating on Adverum Biotechnologies (ADVM)markets.businessinsider.com - November 11 at 1:21 PMAdverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlightsfinance.yahoo.com - November 9 at 5:33 PMWhy Is Eye Disease-Focused Adverum Bio Stock Trading Higher Today?msn.com - November 6 at 3:57 PMAdverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of Directorsfinance.yahoo.com - November 6 at 9:40 AMMizuho backs Adverum Biotechnologies despite revenue decrease forecastinvesting.com - November 5 at 10:11 PMAdverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023benzinga.com - November 4 at 8:03 PMAdverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023finance.yahoo.com - November 4 at 8:03 PMMizuho Initiates Coverage of Adverum Biotechnologies (ADVM) with Buy Recommendationmsn.com - November 3 at 8:40 AM10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysisfinance.yahoo.com - October 24 at 1:09 PMAdverum Biotechnologies to Participate in Upcoming Investor Conferencesfinance.yahoo.com - September 21 at 6:08 PMTruist Securities Reiterates Adverum Biotechnologies (ADVM) Buy Recommendationmsn.com - September 6 at 6:59 PMAdverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - September 5 at 4:20 PMAdverum Biotechnologies (ADVM) Price Target Increased by 13.33% to 4.34msn.com - August 31 at 8:16 AMAdverum Biotechnologies, Inc.: Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology Officerfinanznachrichten.de - August 22 at 7:31 AMAdverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology Officerfinance.yahoo.com - August 21 at 4:30 PMAdverum Biotechnologies (NASDAQ:ADVM) Now Covered by Analysts at StockNews.commarketbeat.com - August 17 at 2:43 AMAdverum Biotechnologies to Participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conferencefinance.yahoo.com - August 14 at 9:28 AMChardan Capital Upgrades Adverum Biotechnologies (ADVM)msn.com - August 12 at 3:52 PMAdverum upgraded at Chardan ahead of key readouts for lead assetmsn.com - August 11 at 7:50 PMAdverum Biotechnologies (NASDAQ:ADVM) Rating Increased to Buy at Chardan Capitalmarketbeat.com - August 11 at 8:00 AMAdverum Biotechnologies (ADVM) Price Target Increased by 7.14% to 3.83msn.com - August 2 at 7:48 AMShort Volatility Alert: Adverum Biotechnologiesbenzinga.com - June 22 at 1:53 PMAdverum Biotechnologies Grants License to Ray Therapeutics Inc. for the AAV.7m8 Intravitreal Capsidfinance.yahoo.com - June 12 at 4:15 PMGSA Capital Partners LLP Acquires 751,753 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM)marketbeat.com - June 7 at 7:27 AMAdverum Biotechnologies to Participate in the Jefferies Healthcare Conferencefinance.yahoo.com - June 2 at 8:47 AMAdverum Biotechnologies Announces New Executive Leadership Rolesfinance.yahoo.com - May 25 at 11:09 AMAdverum Biotechnologies Presents Nonclinical Data in Support of Ixo-vec's Phase 2 Clinical Development at ASGCT 2023 Annual Meetingtechnews.tmcnet.com - May 18 at 2:22 PMAdverum Biotechnologies Introduces an Intravitreal Gene Therapy Program for Geographic Atrophy and Presents Data on Its Ocular Gene Therapy Platformfinance.yahoo.com - May 18 at 9:18 AMAdverum Biotechnologies Presents Nonclinical Data in Support of Ixo-vec’s Phase 2 Clinical Development at ASGCT 2023 Annual Meetingfinance.yahoo.com - May 18 at 9:18 AMAdverum Biotechnologies (ADVM) Receives a Hold from RBC Capitalmarkets.businessinsider.com - May 16 at 1:50 AMAdverum Biotechnologies Reports First Quarter 2023 Financial Resultsfinance.yahoo.com - May 11 at 7:14 PMAdverum Biotechnologies to Participate in RBC Capital Markets Global Healthcare Conferencefinance.yahoo.com - May 10 at 7:31 PMAdverum Biotechnologies Announces Upcoming Data Presentations at ASGCTtmcnet.com - May 2 at 8:31 PMAdverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2023 including Data on a New Intravitreal (IVT) Geographic Atrophy Secondary to Dry AMDfinance.yahoo.com - May 2 at 8:31 PMAdverum Biotechnologies Presents Nonclinical Data at the 2023 ARVO Annual Meeting Supporting Potential for Staggered Bilateral Administration of Ixo-vecfinance.yahoo.com - April 23 at 2:40 PMAfter losing 12% in the past year, Adverum Biotechnologies, Inc. (NASDAQ:ADVM) institutional owners must be relieved by the recent gainfinance.yahoo.com - April 21 at 7:55 AMAdverum Biotechnologies Granted Innovative Licensing and Access Pathway Designation in the United Kingdom for Ixo-vec for the Treatment of Wet AMDfinance.yahoo.com - April 18 at 8:47 AMAdverum Biotechnologies Announces Upcoming Nonclinical Data Presentation Supporting Staggered Bilateral Administration of Ixoberogene Soroparvovec (Ixo-vec) at the 2023 ARVO Annual Meetingfinance.yahoo.com - April 17 at 4:11 PMAdverum Biotechnologies GAAP EPS of -$0.33 beats by $0.03msn.com - March 31 at 11:00 AMAdverum Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Phase 2 LUNA Trial Updatefinance.yahoo.com - March 30 at 6:26 PMAdverum Biotechn (ADVM) Earnings Dates & Reportsinvesting.com - March 21 at 10:44 PMLadenburg Thalmann Initiates Coverage of Adverum Biotechnologies (ADVM) with Buy Recommendationmsn.com - March 7 at 4:23 PMAdaptive Biotechnologies (ADPT) Shares Cross Above 200 DMAnasdaq.com - January 12 at 7:52 AMGI CELL Enters Agreement with Optieum Biotechnologiesfinance.yahoo.com - January 7 at 8:58 PMAdverum Biotechnologies, Inc.: Adverum Biotechnologies Reports Third Quarter 2022 Financial Resultsfinanznachrichten.de - November 12 at 7:52 AMAdverum Biotechnologies Reports Third Quarter 2022 Financial Resultsfinance.yahoo.com - November 10 at 4:19 PMAdverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)finance.yahoo.com - November 4 at 7:12 PM Get Adverum Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Email Address ADVM Media Mentions By Week ADVM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADVM News Sentiment▼1.420.52▲Average Medical News Sentiment ADVM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADVM Articles This Week▼20▲ADVM Articles Average Week Get Adverum Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: IPSC News CCCC News BCAB News LIFE News MIRO News JSPR News GNTA News CRIS News IKNA News SGMO News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:ADVM) was last updated on 12/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.